Teva Pharmaceutical Industries announced the launch of 1% sodium hyaluronate in the U.S., indicated for treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Link to Statement: Teva Announces Launch of 1% Sodium Hyaluronate in the United States
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.